Phase not reported / not applicableCompletedOBSERVATIONAL
Weight Loss in Adults Using Semaglutide (Real-world Study)
ClinicalTrials.gov · NCT07627074 · Registry updated: 2026-09-04
- Condition / research focus
- Overweight; Obesity
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- United Kingdom · United States
- Registry dates and results
- Start: 2026-05-12. Completion: 2026-06-15 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Novo Nordisk Investigational Site
Seattle, Washington, United States
Site recruitment: Not reported - Novo Nordisk Investigational SiteLondon, United Kingdom